Iodine‐125 low–dose rate prostate brachytherapy.

Robotic‐assisted laparoscopic radical prostatectomy and intensity‐modulated radiation therapy are the most common radical treatments for localized prostate cancer, and brachytherapy (BT) also plays a role in this field. Iodine‐125 (I‐125) low–dose rate (LDR) prostate BT is an established treatment. However, it remains controversial. Specifically, there are a variety of issues, such as indications for combined treatment with external beam radiotherapy and androgen deprivation therapy, prostate‐specific antigen follow‐up, the significance of postimplant biopsy, the usefulness of salvage BT and focal therapy, reduction of toxicities, and bladder cancer after BT. In this review, we summarize the recent developments in I‐125 LDR BT. [ABSTRACT FROM AUTHOR]